Seer Reports 32% Q2 Revenue Growth, Reiterates 2025 $17M-$18M Target

Seer, a life sciences technology company specializing in advanced proteomics, reported strong second quarter fiscal 2025 results with GAAP revenue of $4.1 million, representing a 32% year-over-year increase primarily driven by product sales including their Proteograph assays and SP200 automation instrument. Despite the revenue growth and a 21% reduction in operating expenses, Seer remains unprofitable with a GAAP net loss per share of $0.33 and a net loss of $19.4 million, though this is an improvement from the prior year. The company launched new high-throughput products, including the Proteograph ONE assay and the SP200 instrument, enhancing scalability and efficiency, which supports large-scale proteomics studies. Seer expanded its partnerships, notably collaborating with Korea University on a 20,000-sample cancer study using AI-driven diagnostics, and continues to focus on innovation, intellectual property, and global platform accessibility. Management highlighted ongoing macroeconomic challenges such as tariffs, government funding uncertainties, and constrained customer capital expenditures, which may impact market visibility and sales cycles through the year. With $263.3 million in cash and investments, Seer expressed confidence in having sufficient capital to reach cash flow breakeven, maintaining its full-year 2025 revenue guidance of $17 million to $18 million amid these headwinds.